Pfizer Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Pfizer Ltd. from all sources in a single place.

Load latest

Pfizer Ltd.

01 Oct 2025

4989.50

0.09%

TrumpRx, Medicaid discounts and most-favoured-nation pricing: What Pfizer's agreement means

Business Line

President Donald Trump announced a deal with Pfizer to lower US drug costs by cutting Medicaid prices and aligning new drug prices with other high-income countries. The agreement also includes Pfizer onshoring all imported pharmaceuticals to avoid US tariffs.

ICICI Securities Limited upgraded Pfizer Ltd. to Buy with a price target of 6100.0 on 14 Nov, 2025.

Pfizer strikes drug pricing deal with Trump administration, invests $70 bn in US

Business Line | 01 Oct 2025 2 more

Pfizer Ltd.

01 Oct 2025

4989.50

0.09%

Pfizer to lower prescription drug costs for Medicaid in deal with Trump

Business Standard

Drugmaker Pfizer has agreed to lower drug costs under a deal struck with the Trump administration, President Donald Trump said Tuesday, as he promised similar deals will be struck with other drugmakers facing a threat of tariffs. The announcement, which Trump made with Pfizer CEO Albert Bourla at the White House, came as the Republican president has for months sought to lower drug costs. It also came as Washington faced a federal government shutdown at midnight amid a standoff between Democrats and Republicans over health care and its costs. Under the agreement, New York-based Pfizer will charge most-favoured-nation pricing to Medicaid and guarantee that pricing on newly launched drugs, Trump said. That involves matching the lowest price offered in other developed nations. I can't tell you how big this is," the president said. I think," Bourla said, today we are turning the tide and we are reversing an unfair situation. Trump has been talking for months about the need to lower dru

Number of FII/FPI investors increased from 139 to 158 in Sep 2025 qtr.

Pfizer Ltd.

03 Sep 2025

4989.50

0.09%

Pfizer Defends Covid Shot, Says Trump Deserves Nobel Prize

NDTV Profit

Vaccines have become a political flashpoint in recent years, with pundits questioning widely accepted evidence about their safety and efficacy.

Pfizer Ltd. is trading below its 30 day SMA of 5149.2

Pfizer Ltd.

01 Sep 2025

4989.50

0.09%

'Want The Answer Now': Trump Wants Pfizer, Other Drugmakers To Justify Covid Vaccine Success

NDTV Profit

Trump claimed that companies like Pfizer had shown him "extraordinary" results but were not sharing them with the public.

Pfizer Ltd. is trading below its 30 day SMA of 5149.2

Pfizer Ltd.

28 Aug 2025

4989.50

0.09%

Why getting Covid-19 vaccine is likely to be more complicated this year?

Business Line

The US Food and Drug Administration has OK'd new shots from Pfizer, Moderna and Novavax, but the approvals came with some new caveats

Number of FII/FPI investors increased from 139 to 158 in Sep 2025 qtr.

Pfizer Ltd.

13 Aug 2025

4989.50

0.09%

Pfizer Q1 Results: Net Profit Climbs 27%, Margins Expand

NDTV Profit

The drugmaker's bottom-line soared to Rs 191.75 crore during the April-June period, compared to Rs 150.71 crore for the same period last year.

Pfizer Ltd. has an average target of 6100.00 from 1 broker.

Pfizer Ltd.

13 Aug 2025

4989.50

0.09%

Board Meeting

Pfizer Ltd - 500680 - Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial …

BSE India

Unaudited Financial Results for quarter ended June 30, 2025

pdf

Pfizer Ltd.

13 Aug 2025

4989.50

0.09%

Result

Pfizer Ltd - 500680 - Outcome Of Board Meeting - Unaudited Financial Results For The Quarter …

BSE India

Unaudited Financial results for the quarter ended June 30, 2025

pdf

Pfizer Ltd.

12 Aug 2025

4989.50

0.09%

Pfizer share price up 3% on rolling out this vaccine; key details inside

Business Standard

Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India.

Pfizer Ltd. is trading above its 200 day SMA of 4935.4

Pfizer Launches Next-Gen Vaccine For Pneumococcal Disease

NDTV Profit | 11 Aug 2025

Pfizer Ltd.

11 Aug 2025

4989.50

0.09%

Company Update

Pfizer Ltd - 500680 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pfizer Launches 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV20) for Adults in India, offering broad protection against Pneumococcal Disease.

pdf

Is Pfizer Ltd. worth buying?

213 Votes:

Buy 74.18%

Sell 14.55%

Hold 11.27%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf

34.81% Gain from 52W Low

Pfizer Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Pfizer Ltd. from all sources in a single place.